会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Humanized anti-human α9-integrin antibody
    • 人源化抗人α9整联蛋白抗体
    • US08603476B2
    • 2013-12-10
    • US12812341
    • 2009-01-09
    • Kenji UeharaHirofumi HiguchiToshihiro NakashimaDaisuke IshikawaNobuchika YamamotoHirotada FujitaFumihiko Sakai
    • Kenji UeharaHirofumi HiguchiToshihiro NakashimaDaisuke IshikawaNobuchika YamamotoHirotada FujitaFumihiko Sakai
    • A61K39/395
    • C07K16/2839C07K2317/24C07K2317/565C07K2317/76C07K2317/92C07K2317/94
    • The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human α9 integrin in the pathogenesis, which uses the antibody.
    • 本发明提供与供体小鼠抗人α9整联蛋白抗体相比具有改善的活性和/或性质的人源化抗人α9整联蛋白抗体,即包含重链可变区的人源化抗人α9整联蛋白抗体,其包含 的SEQ ID NO:11所示的氨基酸序列和由SEQ ID NO:17所示的氨基酸序列组成的轻链可变区,含有重链可变区的人源化抗人α9整联蛋白抗体包含由 由SEQ ID NO:13所示的氨基酸序列和由SEQ ID NO:17所示的氨基酸序列组成的轻链可变区,含有重链可变区的人源化抗人α9整联蛋白抗体 由SEQ ID NO:15所示的氨基酸序列和由SEQ ID NO:9所示的氨基酸序列组成的轻链可变区,以及预防或治疗涉及 人类α9整联蛋白在发病机制中使用抗体。
    • 8. 发明授权
    • Use of immunosuppressants for MMP mediated diseases
    • 免疫抑制剂用于MMP介导的疾病
    • US06833353B1
    • 2004-12-21
    • US09786359
    • 2001-03-14
    • Nobuchika YamamotoHarumi YamazakiTakeshi IshikawaShigeru JohkiFumihiko Sakai
    • Nobuchika YamamotoHarumi YamazakiTakeshi IshikawaShigeru JohkiFumihiko Sakai
    • A61K3800
    • A61K38/13A61K31/00A61K31/436Y10S514/886
    • A new use of immunosuppressant for treating or preventing MMp-medicated diseases is provided. The preferred immunosuppresants are tacrolimus, cyclosporing A or 33-epi-chloro-33-desoxyascomycin (pimecrolimus). Particularly, preferable MMP-mediated diseases are the diseases or conditions caused by gelatinase and/or collagenase, and/or inflammatory diseases concerned with gelatinase; such as arthritis (e.g., osteoarthritis, rheumatoid arthritis, etc.) cerebral diseases (e.g., stroke, etc.), tissue ulceration (e.g., corneal, epidermal and gastriculceration, etc.), abnormal wound healing, periodontal diseases, bone diseases (e.g., Paget's diseases, osteoporosis. etc.), tumor growth, tumor metastasis or invasion, HIV-infection, decubitus, decubitis ulcer, restenosis, epidermolysis bullosa, sepsis, septic shock, neoplasm, psoriasis, neovascularization and multiple sclerosis.
    • 提供了一种新的免疫抑制剂用于治疗或预防MMP药物疾病的新用途。 优选的免疫抑制剂是他克莫司,环孢菌素A或33-表氯-3-脱氧菌丝霉素(吡美莫司)。 特别地,优选的MMP介导的疾病是由明胶酶和/或胶原酶引起的疾病或病症,和/或与明胶酶相关的炎性疾病; 例如关节炎(例如骨关节炎,类风湿性关节炎等)脑疾病(例如中风等),组织溃疡(例如角膜,表皮和胃溃疡等),异常伤口愈合,牙周病,骨病( 例如佩吉特氏病,骨质疏松症等),肿瘤生长,肿瘤转移或侵袭,HIV感染,褥疮,褥疮性溃疡,再狭窄,大疱性表皮松解,败血症,败血性休克,肿瘤,牛皮癣,新生血管形成和多发性硬化。